Acorda Therapeutics Inc (ACOR)

23.60
0.30 1.26
NASDAQ : Health Care
Prev Close 23.90
Open 23.95
Day Low/High 23.40 / 24.10
52 Wk Low/High 23.85 / 43.63
Volume 394.11K
Avg Volume 780.40K
Exchange NASDAQ
Shares Outstanding 46.65M
Market Cap 1.09B
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACOR,GPS,MSB,PNNT,STFC,USG,VCO Downgrades: EXEL,JCI,NCS,PEIX Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Acorda Therapeutics, Inc.

INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Acorda Therapeutics, Inc.

Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Acorda Therapeutics, Inc.

ACORDA THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics, Inc. To Contact The Firm

ACORDA THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Acorda Therapeutics, Inc.

Acorda Adopts Shareholder Rights Plan

Acorda Adopts Shareholder Rights Plan

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that its Board of Directors has adopted a Shareholder Rights Plan, effective September 1, 2017, and declared a dividend distribution of one preferred share purchase...

Acorda Therapeutics, Inc. Investor Alert: Legal Investigation For Potential Securities Law Violations

Acorda Therapeutics, Inc. Investor Alert: Legal Investigation For Potential Securities Law Violations

Girard Gibbs LLP is investigating claims on behalf of investors of Acorda Therapeutics, Inc.

ACORDA THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics, Inc. To Contact The Firm

ACORDA THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Acorda Therapeutics, Inc.

INVESTOR ALERT: Investigation Of Acorda Therapeutics Announced By Holzer & Holzer

INVESTOR ALERT: Investigation Of Acorda Therapeutics Announced By Holzer & Holzer

Holzer & Holzer, LLC is investigating whether Acorda Therapeutics, Inc.

Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers

Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers

The firm received a "refusal to file letter" from the FDA regarding the new drug application for Inbrija, a potential treatment for Parkinson's disease.

Acorda Receives Refusal To File Letter From FDA For INBRIJA™ (CVT-301, Levodopa Inhalation Powder) New Drug Application

Acorda Receives Refusal To File Letter From FDA For INBRIJA™ (CVT-301, Levodopa Inhalation Powder) New Drug Application

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it received a Refusal to File (RTF) letter from the U.

Acorda Stiff-Arms Investor's Demand for Sale

Acorda Stiff-Arms Investor's Demand for Sale

Scopia said losing a legal battle over patents was a watershed moment for Acorda that demands a new strategy.

Acorda Provides Financial And Pipeline Update For Second Quarter 2017

Acorda Provides Financial And Pipeline Update For Second Quarter 2017

Acorda Therapeutics, Inc. (Nasdaq: ACOR) provided a financial and pipeline update for the second quarter ended June 30, 2017.

September 15th Options Now Available For Acorda Therapeutics (ACOR)

Investors in Acorda Therapeutics Inc saw new options begin trading today, for the September 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACOR options chain for the new September 15th contracts and identified one put and one call contract of particular interest.

These Are the Best Growth Stocks Right Now in Biotech

These Are the Best Growth Stocks Right Now in Biotech

Top names.

Short Interest Makes 16% Move For ACOR

Short Interest Makes 16% Move For ACOR

The most recent short interest data has been released for the 06/30/2017 settlement date, which shows a 1,046,512 share increase in total short interest for Acorda Therapeutics Inc , to 7,545,998, an increase of 16.10% since 06/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Acorda Second Quarter 2017 Update Webcast/Conference Call Scheduled For July 27, 2017

Acorda Second Quarter 2017 Update Webcast/Conference Call Scheduled For July 27, 2017

Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to review its second quarter 2017 financial results and pipeline updates on Thursday, July 27 at 8:30 a.

Acorda Submits New Drug Application To U.S. Food And Drug Administration For INBRIJATM (CVT-301, Levodopa Inhalation Powder)

Acorda Submits New Drug Application To U.S. Food And Drug Administration For INBRIJATM (CVT-301, Levodopa Inhalation Powder)

Acorda Therapeutics, Inc. (NASDAQ: ACOR) has submitted a New Drug Application (NDA) to the U.

Biotech Insider Just Loaded Up $234 Million Worth the Stock

Biotech Insider Just Loaded Up $234 Million Worth the Stock

Massive biotech bet!

Biotech Movers: Adamis Shares Jump After FDA Approves Epinephrine Pre-filled Syringe

Biotech Movers: Adamis Shares Jump After FDA Approves Epinephrine Pre-filled Syringe

Adamis Pharmaceuticals, Impax Laboratories and Accorda Therapeutics were among the biotech stock movers in premarket trading on June 16.

Biotech Movers: Albany Molecular Shares Soar on Sale to PE Firms

Biotech Movers: Albany Molecular Shares Soar on Sale to PE Firms

Albany Molecular Research, Acorda Therapeutics and PTC Therapeutics were among the biotech stock movers in premarket trading on Tuesday.

Acorda Presenting New Tozadenant Data At 2017 MDS Congress

Acorda Therapeutics, Inc. (Nasdaq: ACOR) is presenting new data from clinical and preclinical studies of tozadenant at the 2017 International Congress of Parkinson's Disease and Movement Disorders (MDS), being held in...

CVT-301 Phase 3 Data Showed Significantly Improved Motor Function During OFF Periods In Parkinson's Disease

Acorda Therapeutics, Inc. (Nasdaq: ACOR) presented data from its Phase 3 SPAN-PD clinical trial of CVT-301 (levodopa inhalation powder) that showed a statistically significant, clinically meaningful improvement in motor...

Acorda To Present At The Goldman Sachs Healthcare Conference

Acorda Therapeutics, Inc. (Nasdaq: ACOR) will present at the Goldman Sachs Global Healthcare Conference on Wednesday, June 14, 2017 at 8:40 a.

Oversold Conditions For Acorda Therapeutics (ACOR)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Acorda To Present New INBRIJA™ (Levodopa Inhalation Powder) Phase 3 Data At Upcoming MDS Congress

Acorda Therapeutics, Inc. (Nasdaq: ACOR) will present new data from the Phase 3 clinical trial of INBRIJA TM (levodopa inhalation powder) at the International Congress of Parkinson's Disease and Movement Disorders (MDS),...

TheStreet Quant Rating: C- (Hold)